Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension

Advances in Therapy

Volumn 26, Issue 7, 2009, Pages 700-710

  Riccioni, Graziano ^a   Vitulano, Nicola ^b   D'Orazio, Nicolantonio ^c   Bellocci, Fulvio ^b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aliskiren; Hypertension; Renin; Renin inhibitor; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; ALLOPURINOL; AMLODIPINE; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; LISINOPRIL; LOSARTAN; MEVINOLIN; PLACEBO; RAMIPRIL; RENIN; VALSARTAN; WARFARIN; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

AREA UNDER THE CURVE; BACKACHE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; JUXTAGLOMERULAR CELL; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TISSUE PERFUSION; VASOCONSTRICTION; ANIMAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 73349127055     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0050-5     Document Type: Review

References (46)

1. A.V. Chobanian G.L. Bakris H.R. Black 2003 The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA. 289 2560 2572 12748199 10.1001/jama.289.19.2560 1:CAS:528:DC%2BD3sXjvFCqtrk%3D (Pubitemid 37430158)
2. C.A. Sanoski 2009 Aliskiren: an oral direct renin inhibitor for the treatment of hypertension Pharmacotherapy. 29 193 212 19170589 10.1592/phco.29.2.193 1:CAS:528:DC%2BD1MXjtFGjsLc%3D
3. R.W. Piepho J. Beal 2000 An overview of antihypertensive therapy in the 20th century J Clin Pharmacol. 40 967 77 10975068 10.1177/00912700022009693 1:CAS:528:DC%2BD3cXmsF2nsLk%3D
4. Guyton A, Hall J. Fisiologia Medica. 2nd edition. Oxford, UK: Oxford University Press;. 1997:204-206.
5. S.A. Atlas 2007 The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition J Manag Care Pharm. 13 SupplS-b S9 S20
6. T.L. Reudelhuber 2005 The renin-angiotensin system: peptides and enzymes beyond angiotensin II Curr Opin Nephrol Hypertens. 14 155 159 15687842 1:CAS:528:DC%2BD2MXjtFWjsLs%3D
7. A. Stanton 2003 Therapeutic potential of renin inhibitors in the management of cardiovascular disorders Am J Cardiovasc Drugs. 3 389 394 14728059 10.2165/00129784-200303060-00002 1:CAS:528:DC%2BD2cXlvVehsQ%3D%3D (Pubitemid 38008675)
8. R.M. Carey H.M. Siragy 2003 Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation Endocr Rev. 24 261 271 12788798 10.1210/er.2003-0001 1:CAS:528: DC%2BD3sXlsFWqs7w%3D
9. J.W. Funder 2002 New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone Am Heart J. 144 S8 11 12422135 10.1067/mhj.2002.129971 1:CAS:528:DC%2BD38XpsVWntL4%3D (Pubitemid 35316399)
10. L. J. Skeggs J.R. Kahn K. Lentz N.P. Shumway 1957 The preparation, purification, and amino acid sequence of a polypeptide renin substrate J Exp Med. 106 439 543 13463253 10.1084/jem.106.3.439 1:CAS:528:DyaG2sXpvFGgtg%3D%3D
11. A. Forclaz M. Maillard J. Nussberger H.R. Brunner M. Burnier 2003 Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension. 41 31 36 12511526 10.1161/01.HYP.0000047512.58862.A9 1:CAS:528:DC%2BD38Xps1Ogsrk%3D (Pubitemid 36056788)
12. M. Burnier H.R. Brunner 2000 Angiotensin II receptor antagonists Lancet. 19;355 637 645 10.1016/S0140-6736(99)10365-9
13. A.U. Klingbeil S. John M.P. Schneider J. Jacobi R. Handrock R.E. Schmieder 2003 Effect of AT1 receptor blockade on endothelial function in essential hypertension Am J Hypertens. 16 123 128 12559678 10.1016/S0895- 7061(02)03154-0 1:CAS:528:DC%2BD3sXhsVWkurs%3D (Pubitemid 36143430)
14. J.M. Wood J. Maibaum J. Rahuel 2003 Structurebased design of aliskiren, a novel orally effective renin inhibitor Biochem Biophys Res Commun. 308 698 705 12927775 10.1016/S0006-291X(03)01451-7 1:CAS:528:DC%2BD3sXmsVGkt7k%3D (Pubitemid 36976519)
15. N.D. Fisher N.K. Hollenberg 2005 Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 16 592 599 15703270 10.1681/ASN.2004100874 1:CAS:528:DC%2BD2MXis12gurs%3D (Pubitemid 41725095)
16. J. Maibaum D.L. Feldman 2003 Renin inhibitors as novel treatments for cardiovascular disease Expert Opin Ther Patents. 13 589 603 10.1517/13543776.13. 5.589 1:CAS:528:DC%2BD3sXjs1Kntrc%3D (Pubitemid 36622214)
17. J.L. Pool 2007 Direct renin inhibition: focus on aliskiren J Manag Care Pharm. 13 SupplS-b S21 S33
18. B.-H. Oh J. Mitchell J.R. Herron J. Chung M. Khan D.L. Keefe 2007 Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension J Am Coll Cardiol. 49 1157 1163 17367658 10.1016/j.jacc.2006.11.032 1:CAS:528: DC%2BD2sXjtVagurk%3D (Pubitemid 46400330)
19. A. Stanton C. Jensen J. Nussberger E. O'Brien 2003 Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren Hypertension 42 1137 1143 14597641 10.1161/01.HYP.0000101688.17370.87 1:CAS:528:DC%2BD3sXpsVGisrg%3D (Pubitemid 37549068)
20. A.H. Gradman R.E. Schmieder R.L. Lins J. Nussberger Y. Chiang M.P. Bedigian 2005 Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation. 111 1012 1018 15723979 10.1161/01.CIR. 0000156466.02908.ED 1:CAS:528:DC%2BD2MXhsFShu70%3D (Pubitemid 40354519)
21. R.H. Strasser J.G. Puig C. Farsang M. Croket J. Li H. van Ingen 2007 A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension J Hum Hypertens. 21 780 787 17541390 10.1038/sj.jhh.1002220 1:CAS:528:DC%2BD2sXhtVKhsrrK (Pubitemid 47450003)
22. K. Andersen M.H. Weinberger B. Egan 2008 Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial J Hypertens. 26 589 99 18300872 10.1097/HJH.0b013e3282f3ad9a 1:CAS:528:DC%2BD1cXisVWhur0%3D (Pubitemid 351317270)
23. J. Jordan S. Engeli S.W. Boye S. Le Breton D.L. Keefe 2007 Direct renin inhibition with aliskiren in obese patients with arterial hypertension Hypertension. 49 1047 1055 17353513 10.1161/HYPERTENSIONAHA.106.084301 1:CAS:528:DC%2BD2sXktFagsLc%3D (Pubitemid 351664315)
24. Y. Uresin A.A. Taylor C. Kilo 2007 Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension J Renin Angiotensin Aldosterone Syst. 8 190 198 18205098 10.3317/jraas.2007.028 1:CAS:528:DC%2BD1cXhs1yqsLY%3D (Pubitemid 351166266)
25. J.L. Pool R.E. Schmieder M. Azizi 2007 Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan Am J Hypertens. 20 11 20 17198906 10.1016/j.amjhyper.2006.06.003 1:CAS:528:DC%2BD2sXhsFGjsA%3D%3D (Pubitemid 46014059)
26. S. Oparil S.A. Yarows S. Patel F. Hui J. Zhang A. Satlin 2007 Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial Lancet. 370 221 229 17658393 10.1016/S0140-6736(07)61124-6 1:CAS:528:DC%2BD2sXnvF2gsrc%3D (Pubitemid 47069535)
27. W. Drummond M.A. Munger M.R. Essop M. Maboudian M. Khan D.L. Keefe 2007 Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy J Clin Hypertens. 9 742 750 10.1111/j.1524-6175.2007.06614.x 1:CAS:528:DC%2BD2sXht12rt7%2FK
28. S.D. Solomon E. Appelbaum W.J. Manning 2009 Aliskiren in left ventricular hypertrophy (ALLAY) trial investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy Circulation. 119 530 537 19153265 10.1161/CIRCULATIONAHA.108.826214 1:CAS:528:DC%2BD1MXpt1eksA%3D%3D
29. A. Seed R. Gardner J. McMurray 2007 Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure Eur J Heart Fail. 9 1120 1127 17945530 10.1016/j.ejheart.2007.09.002 1:CAS:528: DC%2BD2sXht1ams7fM (Pubitemid 47633316)
30. B. Pitt J.J. McMurray R. Latini 2007 Neurohumoral effects of a new oral direct renin inhibitor in stable heart failure: the aliskiren observation of heart failure treatment study (ALOFT) Circulation. 116 II549
31. H.H. Parving P. Frederik J.B. Lewis E.J. Lewis N.K. Hollenberg AVOID Study Investigators 2008 Aliskiren combined therapy with losartan in type 2 diabetes and nephropathy N Engl J Med. 358 2433 46 18525041 10.1056/ NEJMoa0708379 1:CAS:528:DC%2BD1cXmvFKmtLY%3D (Pubitemid 351793017)
32. S. Vaidyanathan J. Jermany C. Yeh M.N. Bizot R. Camisasca 2006 Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects Br J Clin Pharmacol. 62 690 698 17118124 10.1111/j.1365-2125.2006.02696.x 1:CAS:528:DC%2BD2sXktlarug%3D%3D (Pubitemid 44749546)
33. C. Zhao S. Vaidyanathan C.M. Yeh M. Maboudian H. Armin Dieterich 2006 Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus Clin Pharmacokinet. 45 1125 1134 17048976 10.2165/00003088-200645110-00006 1:CAS:528:DC%2BD28XhtlWhtbnE (Pubitemid 44631391)
34. Tekturna (aliskiren) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
35. W. Dieterle S. Corynen S. Vaidyanathan J. Mann 2005 Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine Int J Clin Pharmacol Ther. 43 527 535 16300168 1:CAS:528:DC%2BD2MXht1GiurjL
36. S. Vaidyanathan J. Valencia C. Kemp 2006 Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers Int J Clin Pract. 60 1343 1356 17073832 10.1111/j.1742-1241.2006.01164.x 1:CAS:528: DC%2BD28Xhtlajt77L (Pubitemid 44560330)
37. S. Ayalasomayajula S. Tchaloyan C.M. Yeh 2008 A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects Curr Med Res Opin. 24 717 726 18234150 10.1185/030079908X260934 1:CAS:528:DC%2BD1cXkvValurg%3D
38. W. Dieterle S. Corynen J. Mann 2004 Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects Br J Clin Pharmacol. 58 433 436 15373937 10.1111/j.1365-2125.2004.02160.x 1:CAS:528:DC%2BD2cXpsVShsL0%3D (Pubitemid 39312468)
39. S. Vaidyanathan C. Reynolds C.M. Yeh 2007 The pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with the P-glycoprotein modulators ketoconazole, digoxin, and atorvastatin in healthy subjects Clin Pharmacol Ther. 81 S109
40. C. Zhao S. Vaidyanathan H.A. Dieterich C. Yeh D. Howard W.P. Dole 2007 Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers Clin Pharmacol Ther. 81 S110
41. K.L. Ong B.M. Cheung Y.B. Man C.P. Lau K.S. Lam 2007 Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004 Hypertension 49 69 75 17159087 10.1161/01.HYP.0000252676.46043.18 1:CAS:528:DC%2BD28XhtlSrs7vI (Pubitemid 46360343)
42. K. Berra N. Houston Miller 2009 Inhibiting the renin-angiotensin system: why and in which patients J Am Acad Nurse Pract. 21 66 75 19125897 10.1111/j.1745-7599.2008.00374.x
43. H. Krum 2008 Role of renin in heart failure and therapeutic potential of direct renin inhibition J Renin Angiotensin Aldosterone Syst. 9 177 180 18957389 10.1177/1470320308097416
44. H.Y. Lee B.H. Oh 2009 Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program Expert Rev Cardiovasc Ther. 7 251 257 19296761 10.1586/14779072.7.3.251 1:CAS:528:DC%2BD1MXjtlOntrY%3D
45. H.H. Parving B.M. Brenner J.J. McMurray 2009 Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design Nephrol Dial Transplant. 24 1663 1671 19145003 10.1093/ndt/gfn721 1:CAS:528:DC%2BD1MXkvFKjsLs%3D
46. P. Verdecchia F. Angeli G. Mazzotta G. Gentile G. Reboldi 2008 The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction Vasc Health Risk Manag. 4 971 981 19183745 1:CAS:528:DC%2BD1cXhsFWgs73E